LightPath Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2016, the third quarter of fiscal 2016, with nine-month results compared with the period ended March 31, 2015. The filing is dated May 5, 2016. The request metadata labels the period “2015 Q3,” but the filing itself reports fiscal 2016 Q3.
Business context
LightPath manufactures precision molded optics, fiber-optic collimators, GRADIUM glass lenses, infrared products, and optical assemblies. It serves industrial, telecommunications, defense, medical, laser, and other markets, with manufacturing centered at its lower-cost Zhenjiang, China facility.
Financial performance
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue, 2016 | $4.11 million | $12.54 million |
| Revenue, prior year | $3.20 million | $9.16 million |
| Revenue growth | 29% | 37% |
| Gross margin | $2.22 million; 54%, versus 50% | $6.84 million; 55%, versus 42% |
| Operating income (loss) | $213,000, versus $207,000 | $1.49 million, versus a $707,000 loss |
| Net income (loss) | $776,000, versus $90,000 | $1.08 million, versus a $348,000 loss |
| EPS, diluted | $0.04, versus $0.01 | $0.06, versus a $0.02 loss |
- Quarterly gross margin improved with higher sales volume, product mix and pricing, manufacturing overhead absorption, benefits from the Zhenjiang facility, and improved infrared yields.
- Quarterly net income included $662,000 of noncash income from remeasuring warrant liabilities. Excluding the warrant fair-value change, the company reported non-GAAP adjusted net income of $114,000, down from $195,000 a year earlier. Nine-month adjusted net income was $1.11 million, versus an adjusted net loss of $723,000.
- Quarterly adjusted EBITDA, a non-GAAP measure, was $469,000, versus $316,000; nine-month adjusted EBITDA was $1.88 million, versus a $303,000 loss.
- SG&A rose by $667,000 in the quarter and $1.21 million year to date. Drivers included management bonus accruals, wages reclassified from product development, a $100,000 sales-agreement termination payment, and higher shareholder-meeting, legal, travel, and other costs.
Cash, liquidity, and obligations
- Cash and cash equivalents were $2.86 million at March 31, 2016, up from $1.64 million at June 30, 2015. Working capital was approximately $7.59 million.
- Nine-month operating cash flow was positive $1.24 million, compared with negative $665,000 in the prior-year period. Investing cash outflow was $750,000, including $756,000 of equipment purchases; financing cash inflow was $272,000.
- Approximately $1.28 million of cash was held by foreign subsidiaries. China funds are not currently repatriable under the stated retained-earnings threshold; management said it did not expect to need these funds for U.S. operations.
- No borrowings were outstanding on the Avidbank receivables-based line at quarter-end. The facility, with a maximum of $1 million subject to eligible receivables, was extended to December 23, 2016 and is secured by cash, U.S. inventory, and receivables.
- Capital lease obligations totaled approximately $380,000, including $166,000 current. Future minimum operating lease payments were approximately $2.25 million.
Changes, outlook, and risks
- All product groups grew year over year in the first nine months. Quarterly growth was strongest in high-volume molded optics (64%) and non-recurring engineering (577%); the latter is project-dependent and excluded from management’s operating forecasts. Specialty products increased 11% for the quarter and 72% year to date.
- Backlog scheduled for delivery within 12 months was approximately $6.97 million, up from $6.49 million at June 30, 2015. Management reported order intake of about $5.2 million in Q3 and said backlog had recovered after a weak Q1.
- Management expected fiscal Q4 revenue increases in low- and high-volume molded optics, specialty, and infrared products, and anticipated slightly lower SG&A costs. It also described fiscal 2017 growth plans focused on molded optics, specialty, and infrared products. No quantified revenue or earnings guidance was provided.
- Management said it believed resources were adequate for the fiscal 2016 plan and current operations over the coming year, while warning that weaker sales, cost increases, or failure to achieve efficiencies could require additional capital. If financing were unavailable on reasonable terms, it might consider strategic alternatives, including asset or company sale, joint ventures, or licensing.
- Risks highlighted include limited cash resources and possible need for financing, reliance on a few key customers, competition and customer cost pressures, the ability to enter new markets and convert design wins into recurring volume, and the need for capacity investment. Foreign-exchange losses related to the Chinese yuan were approximately $221,000 for the nine-month period.
- The filing reports no legal proceedings, defaults upon senior securities, or off-balance-sheet arrangements. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- How much of reported earnings growth reflects recurring operations versus warrant fair-value movements and other noncash or unusual items.
- Whether backlog converts into shipments and whether recent order intake sustains growth, particularly in telecommunications, medical, and specialty applications.
- Whether higher inventory—$3.67 million, with 178 days of cost of sales in inventory—supports demand or increases working-capital and obsolescence risk.
- The concentration and collectability of customer receivables, and the company’s ability to fund planned capital expenditures while maintaining positive operating cash flow.
- Potential dilution from outstanding options, restricted stock units, and warrants; weighted-average diluted shares exceeded basic shares in the profitable quarter.
- The practical availability of China-held cash and the impact of currency movements and local taxes on future results.